|
1
|
Matalliotakis M, Velegrakis A, Laliotis A,
Niraki E and Trivli A: Exacerbation of neurofibromatosis and
adverse pregnancy outcome. A case report and review of the
literature. Clin Exp Obstet Gynecol. 45:126–128. 2018.
|
|
2
|
Stühler V and Bedke J: Overview of
treatment of localized and metastatic renal cell carcinoma (RCC).
MMW Fortschr Med. 160:45–51. 2018.(In German). PubMed/NCBI View Article : Google Scholar
|
|
3
|
Osawa T, Takeuchi A, Kojima T, Shinohara
N, Eto M and Nishiyama H: Overview of current and future systemic
therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol.
49:395–403. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
McLaughlin SK, Olsen SN, Dake B, De Raedt
T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser C
and Cichowski K: The RasGAP gene, RASAL2, is a tumor and metastasis
suppressor. Cancer Cell. 24:365–378. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Curtis SA, Cohen JV and Kluger HM:
Evolving immunotherapy approaches for renal cell carcinoma. Curr
Oncol Rep. 18(57)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu M, Wu H, Shangguan D, Jiang Y, Li X,
Liu S, Zhou B, Yin T and Gong Z: Immunomodulatory therapies for
renal cell carcinoma. Protein Pept Lett. 25:534–547.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Abel EJ and Wood CG: Cytoreductive
nephrectomy for metastatic RCC in the era of targeted therapy. Nat
Rev Urol. 6:375–383. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Matheu A, Collado M, Wise C, Manterola L,
Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, et
al: Oncogenicity of the developmental transcription factor Sox9.
Cancer Res. 72:1301–1315. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Malki S, Bibeau F, Notarnicola C, Roques
S, Berta P, Poulat F and Boizet-Bonhoure B: Expression and
biological role of the prostaglandin D synthase/SOX9 pathway in
human ovarian cancer cells. Cancer Lett. 255:182–193.
2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lu X, Wan F, Zhang H, Shi G and Ye D:
ITGA2B and ITGA8 are predictive of prognosis in clear cell renal
cell carcinoma patients. Tumour Biol. 37:253–262. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Büttner F, Winter S, Rausch S, Reustle A,
Kruck S, Junker K, Stenzl A, Agaimy A, Hartmann A, Bedke J, et al:
Survival prediction of clear cell renal cell carcinoma based on
gene expression similarity to the proximal tubule of the nephron.
Eur Urol. 68:1016–1020. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hui K, Yue Y, Wu S, Gu Y, Guan B, Wang X,
Hsieh JT, Chang LS, He D and Wu K: The expression and function of
RASAL2 in renal cell carcinoma angiogenesis. Cell Death Dis.
9(881)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang Z, Wang J, Su Y and Zeng Z: RASAL2
inhibited the proliferation and metastasis capability of
nasopharyngeal carcinoma. Int J Clin Exp Med. 8:18765–18771.
2015.PubMed/NCBI
|
|
16
|
Li N and Li S: RASAL2 promotes lung cancer
metastasis through epithelial-mesenchymal transition. Biochem
Biophys Res Commun. 455:358–362. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng
J, Fan J, Wang X, Yue Y, Wu S, et al: RASAL2, a RAS
GTPase-activating protein, inhibits stemness and
epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder
cancer. Cell Death Dis. 8(e2600)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Micalizzi DS and Ford HL:
Epithelial-mesenchymal transition in development and cancer. Future
Oncol. 5:1129–1143. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kohno M and Pouyssegur J: Targeting the
ERK signaling pathway in cancer therapy. Ann Med. 38:200–211.
2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bradham C and McClay DR: p38 MAPK in
development and cancer. Cell Cycle. 5:824–828. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chuang SM, Wang IC and Yang JL: Roles of
JNK, p38 and ERK mitogen-activated protein kinases in the growth
inhibition and apoptosis induced by cadmium. Carcinogenesis.
21:1423–1432. 2000.PubMed/NCBI
|
|
23
|
Wakeman TP, Wyczechowska D and Xu B:
Involvement of the p38 MAP kinase in Cr(VI)-induced growth arrest
and apoptosis. Mol Cell Biochem. 279:69–73. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Otsubo T, Akiyama Y, Hashimoto Y, Shimada
S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and
contributes to gastric carcinogenesis. PLoS One.
6(e16617)2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen Y, Huang Y, Huang Y, Chen J, Wang S
and Zhou J: The prognostic value of SOX2 expression in non-small
cell lung cancer: A meta-analysis. PLoS One.
8(e71140)2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Thu KL, Becker-Santos DD, Radulovich N,
Pikor LA, Lam WL and Tsao MS: SOX15 and other SOX family members
are important mediators of tumorigenesis in multiple cancer types.
Oncoscience. 1:326–335. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang W, Chen Z, Shang X, Tian D, Wang D,
Wu K, Fan D and Xia L: Sox12, a direct target of FoxQ1, promotes
hepatocellular carcinoma metastasis through up-regulating Twist1
and FGFBP1. Hepatology. 61:1920–1933. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kanamaru H, Akino H, Suzuki Y, Noriki S
and Okada K: Prognostic value of nuclear area index in combination
with the world health organization grading system for patients with
renal cell carcinoma. Urology. 57:257–261. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sun M, Abdollah F, Bianchi M, Trinh QD,
Jeldres C, Tian Z, Shariat SF, Widmer H, Zorn K, Menon M, et al: A
stage-for-stage and grade-for-grade analysis of cancer-specific
mortality rates in renal cell carcinoma according to age: A
competing-risks regression analysis. Eur Urol. 60:1152–1159.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lalani AA, McGregor BA, Albiges L,
Choueiri TK, Motzer R, Powles T, Wood C and Bex A: Systemic
treatment of metastatic clear cell renal cell carcinoma in 2018:
Current paradigms, use of immunotherapy, and future directions. Eur
Urol. 75:100–110. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zarrabi K, Fang C and Wu S: New treatment
options for metastatic renal cell carcinoma with prior
anti-angiogenesis therapy. J Hematol Oncol. 10(38)2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang S, Tie J, Wang R, Hu F, Gao L, Wang
W, Wang L, Li Z, Hu S, Tang S, et al: SOX2, a predictor of survival
in gastric cancer, inhibits cell proliferation and metastasis by
regulating PTEN. Cancer Lett. 358:210–219. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Goodlad R: Workshop report: Increased cell
proliferation as a cause of human cancer. Food Cancer Prev.
300–301. 2005.
|
|
34
|
Huang Y, Zhao M, Xu H, Wang K, Fu Z, Jiang
Y and Yao Z: RASAL2 down-regulation in ovarian cancer promotes
epithelial-mesenchymal transition and metastasis. Oncotarget.
5:6734–6745. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Orlichenko LS and Radisky DC: Matrix
metalloproteinases stimulate epithelial-mesenchymal transition
during tumor development. Clin Exp Metastasis. 25:593–600.
2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): Positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Feng M, Bao Y, Li Z, Li J, Gong M, Lam S,
Wang J, Marzese DM, Donovan N, Tan EY, et al: RASAL2 activates RAC1
to promote triple-negative breast cancer progression. J Clin
Invest. 124:5291–5304. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sebolt-Leopold JS and Herrera R: Targeting
the mitogen-activated protein kinase cascade to treat cancer. Nat
Rev Cancer. 4:937–947. 2004.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Suthiphongchai T, Promyart P, Virochrut S,
Tohtong R and Wilairat P: Involvement of ERK1/2 in invasiveness and
metastatic development of rat prostatic adenocarcinoma. Oncol Res.
13:253–259. 2003.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ge X, Fu YM and Meadows GG: U0126, a
mitogen-activated protein kinase kinase inhibitor, inhibits the
invasion of human A375 melanoma cells. Cancer Lett. 179:133–140.
2002.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Graf K, Xi XP, Yang D, Fleck E, Hsueh WA
and Law RE: Mitogen-activated protein kinase activation is involved
in platelet-derived growth factor-directed migration by vascular
smooth muscle cells. Hypertension. 29:334–339. 1997.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Serrano-Oviedo L, Ortega-Muelas M,
García-Cano J, Valero ML, Cimas FJ, Pascual-Serra R,
Fernandez-Aroca DM, Roche O, Ruiz-Hidalgo MJ, Belandia B, et al:
Autophagic cell death associated to Sorafenib in renal cell
carcinoma is mediated through Akt inhibition in an ERK1/2
independent fashion. PLoS One. 13(e0200878)2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Li JK, Chen C, Liu JY, Shi JZ, Liu SP, Liu
B, Wu DS, Fang ZY, Bao Y, Jiang MM, et al: Long noncoding RNA
MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via
inhibiting NPR3 and activating p38-MAPK signaling. Mol Cancer.
16(111)2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wu K, Hu L and Hou J: Selective
suppression of Notch1 inhibits proliferation of renal cell
carcinoma cells through JNK/p38 pathway. Oncol Rep. 35:2795–2800.
2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Uchiyama A, Nayak S, Graf R, Cross M,
Hasneen K, Gutkind JS, Brooks SR and Morasso MI: SOX2 epidermal
overexpression promotes cutaneous wound healing via activation of
EGFR/MEK/ERK signaling mediated by EGFR ligands. J Invest Dermatol.
139:1809–1820.e8. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhou B, Zhu W, Jiang X and Ren C: RASAL2
plays inconsistent roles in different cancers. Front Oncol.
9(1235)2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Uzgare AR, Kaplan PJ and Greenberg NM:
Differential expression and/or activation of P38MAPK, erk1/2, and
jnk during the initiation and progression of prostate cancer 1 1
Prostate 2003;55: 128-39. Urol Oncol. 22:82–83. 2004.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Chen L, He HY, Li HM, Zheng J, Heng WJ,
You JF and Fang WG: ERK1/2 and p38 pathways are required for P2Y
receptor-mediated prostate cancer invasion. Cancer Lett.
215:239–247. 2004.PubMed/NCBI View Article : Google Scholar
|
